524 Shares in HCA Healthcare, Inc. $HCA Bought by D Orazio & Associates Inc.

D Orazio & Associates Inc. acquired a new stake in HCA Healthcare, Inc. (NYSE:HCA) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 524 shares of the company’s stock, valued at approximately $201,000.

Several other hedge funds have also recently added to or reduced their stakes in HCA. Park Place Capital Corp lifted its holdings in shares of HCA Healthcare by 2,336.0% during the second quarter. Park Place Capital Corp now owns 1,218 shares of the company’s stock valued at $474,000 after acquiring an additional 1,168 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in HCA Healthcare by 11.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 25,454 shares of the company’s stock valued at $8,796,000 after purchasing an additional 2,698 shares during the last quarter. Harrell Investment Partners LLC grew its stake in HCA Healthcare by 176.3% during the second quarter. Harrell Investment Partners LLC now owns 1,815 shares of the company’s stock worth $695,000 after buying an additional 1,158 shares during the last quarter. Cherokee Insurance Co acquired a new position in shares of HCA Healthcare in the 2nd quarter worth approximately $3,869,000. Finally, Simon Quick Advisors LLC increased its holdings in HCA Healthcare by 616.9% during the 2nd quarter. Simon Quick Advisors LLC now owns 7,147 shares of the company’s stock valued at $2,738,000 after purchasing an additional 6,150 shares in the last quarter. Institutional investors and hedge funds own 62.73% of the company’s stock.

HCA Healthcare Stock Performance

Shares of HCA Healthcare stock opened at $473.42 on Friday. HCA Healthcare, Inc. has a 52 week low of $289.98 and a 52 week high of $479.43. The stock has a market capitalization of $108.03 billion, a price-to-earnings ratio of 18.30, a PEG ratio of 1.38 and a beta of 1.41. The firm has a fifty day moving average of $432.52 and a two-hundred day moving average of $395.09.

HCA Healthcare (NYSE:HCA) last announced its quarterly earnings data on Friday, October 24th. The company reported $6.96 EPS for the quarter, topping analysts’ consensus estimates of $5.64 by $1.32. HCA Healthcare had a negative return on equity of 792.25% and a net margin of 8.53%.The business had revenue of $19.16 billion during the quarter, compared to analysts’ expectations of $18.55 billion. During the same period in the previous year, the firm earned $4.90 earnings per share. The firm’s quarterly revenue was up 9.6% compared to the same quarter last year. HCA Healthcare has set its FY 2025 guidance at 27.000-28.000 EPS. As a group, research analysts forecast that HCA Healthcare, Inc. will post 24.98 EPS for the current fiscal year.

HCA Healthcare Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 29th. Shareholders of record on Monday, December 15th will be paid a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Monday, December 15th. HCA Healthcare’s dividend payout ratio is presently 11.13%.

Insiders Place Their Bets

In other news, EVP Michael S. Cuffe sold 3,836 shares of the firm’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $418.84, for a total transaction of $1,606,670.24. Following the sale, the executive vice president owned 31,503 shares of the company’s stock, valued at $13,194,716.52. This trade represents a 10.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Michael R. Mcalevey sold 3,892 shares of the stock in a transaction that occurred on Wednesday, November 5th. The stock was sold at an average price of $473.79, for a total value of $1,843,990.68. Following the sale, the executive vice president directly owned 3,487 shares of the company’s stock, valued at approximately $1,652,105.73. The trade was a 52.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 1.30% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Oppenheimer raised their target price on HCA Healthcare from $400.00 to $500.00 and gave the company an “outperform” rating in a research note on Monday, October 27th. Wolfe Research downgraded shares of HCA Healthcare from an “outperform” rating to a “peer perform” rating in a research note on Monday, July 28th. Royal Bank Of Canada increased their price target on shares of HCA Healthcare from $449.00 to $482.00 and gave the company an “outperform” rating in a research note on Monday, October 27th. Truist Financial upped their price objective on HCA Healthcare from $460.00 to $495.00 and gave the stock a “buy” rating in a report on Monday, October 27th. Finally, Wells Fargo & Company upped their price target on HCA Healthcare from $412.00 to $431.00 and gave the company an “equal weight” rating in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $474.53.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.